Navigation Links
Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad
Date:9/7/2011

SAN DIEGO, Sept. 7, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that it has completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) and successfully reached agreement on the following key aspects of its proposed lesinurad Phase 3 development plan: the overall size and design of the planned Phase 3 clinical studies, the primary endpoints, the total safety database proposed for NDA filing, manufacturing plans for both drug substance and drug product, the preclinical toxicology program and the clinical pharmacology program. The Company continues to target commencing Phase 3 studies before the end of this year. Lesinurad is Ardea's lead product candidate in development for the chronic treatment of gout.  

"There is a major unmet medical need for a well-tolerated, orally administered urate-lowering therapy that works by a novel mechanism of action and can be given alone or in combination with other agents to the many patients who are not adequately treated with currently available products," commented Michael Becker, MD, Professor Emeritus of Medicine, Department of Medicine, University of Chicago Medical Center. "The encouraging safety and efficacy results from Phase 2 clinical trials of lesinurad provide strong support for successful Phase 3 clinical development."

In connection with the Company's Phase 3 development program and as previously announced, the Company recently commenced a multinational, interventional study designed to identify gout patients not reaching target serum uric acid (sUA) levels on allopurinol, currently the most widely prescribed gout medication.  In addition to collecting clinically relevant information on the use of allopurinol, this study will also assist in pre-screening and determining the eligibility of gout patients to enroll into two pivotal Phase 3 studies, which
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results
2. Ardea Biosciences to Present at Upcoming Investor Conferences
3. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
4. Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
5. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
6. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
7. Ardea Biosciences Prices Public Offering of Common Stock
8. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
9. Ardea Biosciences to Present at Two Upcoming Investor Conferences
10. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
11. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014  PDL BioPharma, Inc. (PDL) (NASDAQ: ... registered accounting firm, Ernst & Young LLP ("EY") that it ... in a letter delivered to the Company on September 15, ... 16, 2014.  PDL has issued the following ... received a number of inquiries on the reason for the ...
(Date:9/17/2014)... 17, 2014 A long-term retrospective study ... irradiation (APBI) via interstitial brachytherapy suggests that women ... nodes could be suitable to receive the treatment. ... place these patients in the "unsuitable" category for ... ASTRO meeting, Beaumont Health System,s Peter Y. ...
(Date:9/17/2014)... 17, 2014 The global consumption of squalene / ... is a natural skin-identical chemical that finds applications in various ... supplements, pharmaceuticals, and in other applications like high grade lubrication, ... a few major players and is regionally segregated. Sophim ( ... Oil Co. Ltd. ( Japan ), SeaDragon Marine ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. ... intends to offer and sell shares of its Common ... but concurrent underwritten public offerings.  The Series A Convertible ... Oncothyreon Common Stock, provided that conversion will be prohibited ... would beneficially own more than 4.99% of the Common ...
Breaking Biology Technology:PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3Oncothyreon Announces Proposed Public Offerings 2
... Communications , a provider of enterprise networking components, has ... of communications technology. , ,This funding, part of the ... competitive award process. It will enable the company to ... States Army . , ,The request for funding was ...
... I always like about the annual BIO International Conference ... Young always releases at this event its latest report ... Global Biotechnology Industry 2007. , ,This report is chock ... than Ernst & Young covers the global growth of this ...
... from the Public Company Accounting Oversight Board ... within information systems. There are numerous studies, including our ... area. It is worth making the investment to fix ... savings with your Sarbanes-Oxley compliance program. , ...
Cached Biology Technology:The state of global biotech: An Ernst & Young perspective 2The state of global biotech: An Ernst & Young perspective 3The state of global biotech: An Ernst & Young perspective 4The state of global biotech: An Ernst & Young perspective 5The state of global biotech: An Ernst & Young perspective 6Why IT change management is more important than ever 2Why IT change management is more important than ever 3Why IT change management is more important than ever 4
(Date:9/17/2014)... 17, 2014) A rare genetic disorder known as Jacobsen ... recent joint investigation by researchers at San Diego State ... addition to suggesting better treatment options for people with ... the genetic underpinnings of autism., Jacobsen syndrome affects approximately ... of Health. It occurs in a person when there ...
(Date:9/17/2014)... team of Spanish researchers have obtained the first partial ... sixteenth century pig found at the site of the ... this ancient pig is closely related to today,s Iberian ... were crossed with modern Iberian pigs. , The study, ... evolutionary aspects of pig species, and particularly on that ...
(Date:9/17/2014)... After decades of decline, grasses have returned to ... eye, the marsh in those places seems healthy again, ... service of the marsh coastal protection remains ... ecosystem function hasn,t come back," said ecologist Mark Bertness, ... the study in the journal Biological Conservation . ...
Breaking Biology News(10 mins):A link between Jacobsen syndrome and autism 2Iberian pig genome remains unchanged after 5 centuries 2Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3
... in imaging technology using a combination of light and ... details inside the body. Access to this level of ... but it also has the potential to help health ... symptoms arise. Details describing this advance are published online ...
... Mich. Late-preterm babies those born between 34 and ... and emotional problems, regardless of maternal IQ or demographics, according ... the current edition of the journal Pediatrics . ... have been associated with such problems before, the study represents ...
... more than 60 guides and anglers in the Florida Keys ... assisting in the annual bonefish census. This year,s count, held ... 25-percent from an 8-year mean estimate of 316,805 bonefish to ... Jerry Ault, a fisheries scientist with the University of Miami,s ...
Cached Biology News:Medical imaging breakthrough uses light and sound to see microscopic details inside our bodies 2Late-preterm babies at greater risk for problems later in childhood 2Fall bonefish census sounds warning bell that warrants careful future monitoring 2
The Light Diagnostics Calicivirus Genotype 1&2 Typing OligoDetect assay is applicable for the qualitative detection of calicivirus RNA generated by an in-house validated in vitro nucleic acid amplifi...
X-Gal...
Recombinant Rat CINC-2 alpha, CF...
RABBIT ANTI SRC-RSV...
Biology Products: